Author

Sally Weng

1Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.ORCID 0009-0002-1375-9625Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Charlie A. WhittakeriD· 1 shared Elen Torres-MejiaiD· 1 shared Ellen DuongiD· 1 shared Kim B. NguyeniD· 1 shared Leon YimiD· 1 shared Stefani SprangeriD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Charlie A. WhittakerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ImmunologybioRxivSep 6, 2023

Lung cancer-intrinsic SOX2 expression mediates resistance to checkpoint blockade therapy by inducing Treg-dependent CD8+ T cell exclusion

Elen Torres-Mejia, Sally Weng, Charlie A. Whittaker…·Stefani Spranger

This study identifies SOX2 expression in lung cancer cells as a mechanism causing resistance to checkpoint blockade by promoting Treg-dependent CD8+ T cell exclusion.

DOI 10.1158/2326-6066.cir-24-0184

mousebulk RNA-seq

𝕏 PostBluesky